Wall Street brokerages forecast that Chimerix Inc (NASDAQ:CMRX) will announce earnings of ($0.36) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.43). Chimerix reported earnings per share of ($0.41) during the same quarter last year, which suggests a positive year-over-year growth rate of 12.2%. The company is expected to report its next earnings results on Thursday, March 7th.

On average, analysts expect that Chimerix will report full-year earnings of ($1.50) per share for the current year, with EPS estimates ranging from ($1.57) to ($1.45). For the next year, analysts expect that the firm will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.85) to ($1.22). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Chimerix.

A number of equities research analysts recently commented on CMRX shares. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Monday, January 28th. HC Wainwright reaffirmed a “buy” rating on shares of Chimerix in a report on Wednesday, February 6th. Finally, ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $6.17.

A number of large investors have recently made changes to their positions in the business. HRT Financial LLC acquired a new position in Chimerix in the fourth quarter valued at approximately $40,000. 683 Capital Management LLC acquired a new position in Chimerix in the fourth quarter valued at approximately $771,000. Millennium Management LLC lifted its holdings in Chimerix by 25.4% in the fourth quarter. Millennium Management LLC now owns 325,650 shares of the biopharmaceutical company’s stock valued at $837,000 after acquiring an additional 66,014 shares during the period. Opaleye Management Inc. lifted its holdings in Chimerix by 70.5% in the fourth quarter. Opaleye Management Inc. now owns 2,020,000 shares of the biopharmaceutical company’s stock valued at $5,191,000 after acquiring an additional 835,000 shares during the period. Finally, Paloma Partners Management Co acquired a new position in Chimerix in the fourth quarter valued at approximately $71,000. 73.10% of the stock is owned by institutional investors.

Shares of Chimerix stock traded up $0.02 during trading on Tuesday, hitting $1.99. 252,104 shares of the stock traded hands, compared to its average volume of 284,603. The firm has a market cap of $100.94 million, a P/E ratio of -1.32 and a beta of 1.39. Chimerix has a 52-week low of $1.95 and a 52-week high of $5.94.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: What is the Consumer Price Index (CPI)?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.